Disc Medicine, Inc. (NASDAQ:IRON) Shares Purchased by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its holdings in Disc Medicine, Inc. (NASDAQ:IRON - Free Report) by 399.2% in the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor owned 93,103 shares of the company's stock after purchasing an additional 74,454 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned approximately 0.31% of Disc Medicine worth $5,903,000 at the end of the most recent reporting period.

Other large investors have also recently added to or reduced their stakes in the company. Sterling Capital Management LLC boosted its stake in shares of Disc Medicine by 798.4% in the 4th quarter. Sterling Capital Management LLC now owns 566 shares of the company's stock valued at $36,000 after buying an additional 503 shares during the period. Tower Research Capital LLC TRC raised its holdings in Disc Medicine by 47.6% in the fourth quarter. Tower Research Capital LLC TRC now owns 825 shares of the company's stock valued at $52,000 after acquiring an additional 266 shares in the last quarter. KLP Kapitalforvaltning AS purchased a new position in Disc Medicine in the fourth quarter worth approximately $235,000. Fiduciary Trust Co purchased a new position in Disc Medicine in the fourth quarter worth approximately $257,000. Finally, Bayesian Capital Management LP acquired a new position in Disc Medicine during the 4th quarter worth approximately $285,000. 83.70% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of equities research analysts have recently weighed in on the stock. BMO Capital Markets raised their price objective on shares of Disc Medicine from $112.00 to $120.00 and gave the company an "outperform" rating in a report on Monday, May 12th. Morgan Stanley restated an "overweight" rating and issued a $85.00 price target on shares of Disc Medicine in a research note on Friday, March 7th. Cantor Fitzgerald lifted their price target on Disc Medicine from $99.00 to $132.00 and gave the stock an "overweight" rating in a report on Tuesday, March 18th. Scotiabank increased their price objective on Disc Medicine from $73.00 to $75.00 and gave the company a "sector outperform" rating in a report on Monday, March 3rd. Finally, TD Cowen initiated coverage on Disc Medicine in a research report on Thursday, February 27th. They set a "buy" rating on the stock. Ten equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat.com, the company presently has a consensus rating of "Buy" and a consensus target price of $98.80.

Insider Activity at Disc Medicine

In other news, insider William Jacob Savage sold 2,100 shares of the company's stock in a transaction that occurred on Friday, May 2nd. The stock was sold at an average price of $50.17, for a total transaction of $105,357.00. Following the completion of the sale, the insider now owns 66,398 shares in the company, valued at $3,331,187.66. This represents a 3.07% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Mona Ashiya sold 10,011 shares of the company's stock in a transaction on Friday, March 21st. The stock was sold at an average price of $54.00, for a total transaction of $540,594.00. Following the transaction, the director now owns 187,297 shares of the company's stock, valued at approximately $10,114,038. The trade was a 5.07% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 349,510 shares of company stock worth $18,936,535 in the last 90 days. 4.24% of the stock is owned by insiders.

Disc Medicine Stock Up 2.4%

NASDAQ:IRON traded up $1.13 during mid-day trading on Thursday, reaching $48.45. 250,157 shares of the stock were exchanged, compared to its average volume of 347,724. The stock has a market capitalization of $1.68 billion, a P/E ratio of -12.14 and a beta of 0.77. Disc Medicine, Inc. has a 1 year low of $30.82 and a 1 year high of $68.73. The company has a 50 day simple moving average of $44.78 and a 200-day simple moving average of $53.86.

Disc Medicine (NASDAQ:IRON - Get Free Report) last posted its quarterly earnings data on Wednesday, May 7th. The company reported ($1.02) earnings per share for the quarter, missing the consensus estimate of ($0.99) by ($0.03). As a group, research analysts predict that Disc Medicine, Inc. will post -4.07 EPS for the current year.

Disc Medicine Profile

Disc Medicine, Inc, together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis.